Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darin Allred

Orthopaedic Surgery St George, UT Doctor of Osteopathy

NPI 1538377585 CMS profile 24218

652 S Medical Center Dr, Ste 120, St George, UT 84790

Open in the dashboard

General payments

$34,171

176 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Darin Allred of St George, UT is reported in the CMS Open Payments database as having received $34,171 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,032 51
2024 General $1,078 14
2023 General $635 9
2022 General $580 7
2021 General $1,825 17
2020 General $2,934 26
2019 General $5,087 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darin Allred
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Darin Allred were reported at $22,032. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Darin Allred Orthopaedic Surgery median Middle half National median
2019 $5,087 $644 $140–$2,844 $163
2020 $2,934 $312 $75–$1,860 $114
2021 $1,825 $520 $117–$2,495 $132
2022 $580 $598 $128–$2,731 $149
2023 $635 $461 $128–$2,264 $160
2024 $1,078 $497 $134–$2,475 $164
2025 $22,032 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ortho Development Corporation $14,119 24 payments
  2. DePuy Synthes Sales Inc. $6,415 36 payments
  3. Medical Device Business Services, Inc. $5,467 20 payments
  4. Stryker Corporation $3,712 44 payments
  5. Orthalign Inc $1,063 4 payments
  6. Zimmer Biomet Holdings, Inc. $730 10 payments
  7. MicroPort Orthopedics Inc $716 4 payments
  8. OMNIlife science, Inc $411 5 payments
  9. Boston Scientific Corporation $358 9 payments
  10. Nevro Corp. $155 2 payments
  11. Other $1,025 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,050 5 payments
  2. Travel and Lodging $12,666 34 payments
  3. Food and Beverage $8,456 137 payments
Products named General payments · program years 2019–2025
  1. Trivicta $10,542 8 payments
  2. BKS TriMax $3,369 10 payments
  3. TRIATHLON $1,728 14 payments
  4. LPS $1,725 5 payments
  5. ATTUNE $1,452 7 payments
  6. ORTHALIGN PLUS $1,063 4 payments
  7. TRUESPAN $1,037 6 payments
  8. TRIDENT $984 3 payments
  9. None $916 11 payments
  10. Velys $849 11 payments
  11. Other $5,718 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

358

Median for Orthopedic Surgery: 203

Drug cost

$2,211

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 82 $1,151
Meloxicam Generic 265 $1,009
Oxycodone Hcl Generic 11 $51

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$219,408

Of which drugs: $13,628

Medicare patients

389

Average age 75

Services billed

2,775

225 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 27%
Diabetes 24%
Ischemic heart disease 23%
Chronic kidney disease 22%
Atrial fibrillation 19%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 15 1,008 $7,067
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 16 67 $6,138
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 100 600 $420

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record